GERN Geron Corporation

NASDAQ
$1.47

Geron Corporation (GERN) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.3% since its last earnings release on August 5, 2026.

Geron Missed Consensus Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.01)
Rev est $59.97M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Geron Corporation

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies.

Sector

Healthcare

Industry

Drug Manufacturers/Other